Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Agent Capital is a prominent healthcare venture capital firm founded in Waltham, Massachusetts. Established with a mission to invest in novel and differentiated therapeutics, the firm addresses significant unmet patient needs across various therapeutic areas. Agent Capital focuses on making direct equity investments at all stages of development, from pre-seed to growth equity, partnering with scientists, entrepreneurs, and other investors to advance healthcare innovations. The firm has a strong reputation in the biotech sector, particularly for its strategic investments in companies that are pioneering solutions in rare diseases, oncology, neurology, and immunology.
With a commitment to supporting healthcare advancements, Agent Capital has successfully raised multiple funds, although specific fund sizes and assets under management (AUM) are not publicly disclosed. The firm’s leadership comprises experienced professionals with backgrounds in both science and business, which enhances their ability to evaluate and support innovative healthcare solutions. Their geographic focus is primarily on North America, where they actively seek out investment opportunities that align with their mission to improve patient outcomes.
Agent Capital's investment focus is centered on therapeutic areas with high unmet medical needs, particularly in rare diseases, oncology, neurology, and immunology. The firm participates in a wide range of financing rounds, including pre-seed, seed, Series A, Series B, Series C, and growth equity. This diverse approach allows Agent Capital to engage with companies at various stages of development, from early-stage financings to later-stage investments, including post-Series A and crossover rounds.
The firm is particularly interested in supporting companies that are developing innovative therapeutics and treatments that address critical healthcare challenges. Their investment strategy encompasses preclinical, clinical, and commercial stages of development, ensuring that they can provide the necessary capital and expertise to help their portfolio companies succeed. By focusing on high unmet medical needs, Agent Capital aims to foster advancements that can significantly impact patient care and outcomes.
Agent Capital boasts a notable portfolio of companies that are making significant strides in the healthcare sector. Among their most prominent investments is **Dice Therapeutics**, which focuses on developing innovative medicines in immunology and was acquired by Lilly for $2.4 billion. Another key investment is **ImCheck Therapeutics**, which specializes in immunomodulation and was acquired by Ipsen for €1 billion. Additionally, **Interius BioTherapeutics**, a gene therapy company, was acquired by Kite for $350 million, showcasing Agent Capital's ability to identify and support high-potential biotech firms.
Other noteworthy portfolio companies include **Freenome**, which is pioneering a multiomics platform for early cancer detection, and **Alveus Therapeutics**, which recently raised $197 million in Series A financing to develop next-generation therapies for obesity and metabolic diseases. **Cerevance** is also part of their portfolio, focusing on treatments for CNS disorders and neurodegenerative diseases. This diverse range of investments highlights Agent Capital's commitment to advancing healthcare innovations across various therapeutic areas.
To pitch Agent Capital, founders should email info@agentcapital.com with a concise overview of their business and how it aligns with the firm's focus on healthcare innovations. A clear presentation of the problem being addressed and the proposed solution is essential.
Agent Capital invests across multiple stages, including pre-seed, seed, Series A, Series B, Series C, and growth equity. This broad investment strategy allows them to support companies at various points in their development journey.
Founders interested in pitching Agent Capital can reach out via email at info@agentcapital.com. It is advisable to provide a clear overview of the business, the problem it addresses, and how it aligns with Agent Capital's focus on healthcare innovations.
Agent Capital primarily focuses on the healthcare sector, with specific interests in rare diseases, oncology, neurology, and immunology. They seek to invest in companies that are developing novel therapeutics to address significant unmet medical needs.
While specific check sizes are not disclosed, Agent Capital participates in a wide range of financing rounds, indicating flexibility in their investment amounts depending on the stage and needs of the company.
Agent Capital focuses its investments primarily in North America, seeking out innovative healthcare companies that align with their mission to improve patient outcomes.
Agent Capital offers strategic support to its portfolio companies, leveraging its extensive network and expertise in the healthcare sector to help navigate challenges and drive growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.